Akari Therapeutics plc ADR (0.01 USD)

Akari Therapeutics announced progress in 2025 and outlined its path toward clinical transition in 2026. The company established a manufacturing partnership with WuXi Biologics and initiated pre-filing activities, with plans to launch its First-in-Human clinical trial by late 2026/early 2027. The company's lead candidate AKTX-101 is an ADC targeti...

Akari Therapeutics has successfully completed the merger with Peak Bio, creating an innovative biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The combined entity secured $3.2 million in PIPE financing and a $50 million term sheet for an equity line of credit to support its pipeline development.

Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024

BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. as interim CEO.

BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights.